167 related articles for article (PubMed ID: 35257929)
1. Combination treatment with growth hormone and zoledronic acid in a mouse model of Osteogenesis imperfecta.
Lee LR; Holman AE; Li X; Vasiljevski ER; O'Donohue AK; Cheng TL; Little DG; Schindeler A; Biggin A; Munns CF
Bone; 2022 Jun; 159():116378. PubMed ID: 35257929
[TBL] [Abstract][Full Text] [Related]
2. Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta.
Little DG; Peacock L; Mikulec K; Kneissel M; Kramer I; Cheng TL; Schindeler A; Munns C
Bone; 2017 Aug; 101():96-103. PubMed ID: 28461254
[TBL] [Abstract][Full Text] [Related]
3. Effects of treatment with a bone-targeted prostaglandin E2 receptor 4 agonist C3 (Mes-1007) in a mouse model of severe osteogenesis imperfecta.
Boraschi-Diaz I; Chen G; Polak-Nachumow J; Young RN; Rauch F
Bone; 2021 Apr; 145():115867. PubMed ID: 33524637
[TBL] [Abstract][Full Text] [Related]
4. Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength.
Sinder BP; White LE; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
Osteoporos Int; 2014 Aug; 25(8):2097-107. PubMed ID: 24803333
[TBL] [Abstract][Full Text] [Related]
5. Bone Marrow Transplantation for Treatment of the Col1a2
Lee LR; Peacock L; Ginn SL; Cantrill LC; Cheng TL; Little DG; Munns CF; Schindeler A
Calcif Tissue Int; 2019 Apr; 104(4):426-436. PubMed ID: 30535573
[TBL] [Abstract][Full Text] [Related]
6. Modeling anabolic and antiresorptive therapies for fracture healing in a mouse model of osteogenesis imperfecta.
O'Donohue AK; Dao A; Bobyn JD; Munns CF; Little DG; Schindeler A
J Orthop Res; 2023 Apr; 41(4):808-814. PubMed ID: 35803595
[TBL] [Abstract][Full Text] [Related]
7. Growth hormone injections improve bone quality in a mouse model of osteogenesis imperfecta.
King D; Jarjoura D; McEwen HA; Askew MJ
J Bone Miner Res; 2005 Jun; 20(6):987-93. PubMed ID: 15883639
[TBL] [Abstract][Full Text] [Related]
8. Correlations Between Bone Mechanical Properties and Bone Composition Parameters in Mouse Models of Dominant and Recessive Osteogenesis Imperfecta and the Response to Anti-TGF-β Treatment.
Bi X; Grafe I; Ding H; Flores R; Munivez E; Jiang MM; Dawson B; Lee B; Ambrose CG
J Bone Miner Res; 2017 Feb; 32(2):347-359. PubMed ID: 27649409
[TBL] [Abstract][Full Text] [Related]
9. Impact of Genetic and Pharmacologic Inhibition of Myostatin in a Murine Model of Osteogenesis Imperfecta.
Omosule CL; Gremminger VL; Aguillard AM; Jeong Y; Harrelson EN; Miloscio L; Mastaitis J; Rafique A; Kleiner S; Pfeiffer FM; Zhang A; Schulz LC; Phillips CL
J Bone Miner Res; 2021 Apr; 36(4):739-756. PubMed ID: 33249643
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy in the Col1a2
Kaupp S; Horan DJ; Lim KE; Feldman HA; Robling AG; Warman ML; Jacobsen CM
Bone; 2020 Feb; 131():115084. PubMed ID: 31648079
[TBL] [Abstract][Full Text] [Related]
11. Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment.
Sinder BP; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
Bone; 2015 Feb; 71():115-23. PubMed ID: 25445450
[TBL] [Abstract][Full Text] [Related]
12. Bone mineral properties in growing Col1a2(+/G610C) mice, an animal model of osteogenesis imperfecta.
Masci M; Wang M; Imbert L; Barnes AM; Spevak L; Lukashova L; Huang Y; Ma Y; Marini JC; Jacobsen CM; Warman ML; Boskey AL
Bone; 2016 Jun; 87():120-9. PubMed ID: 27083399
[TBL] [Abstract][Full Text] [Related]
13. Strontium Ranelate Reduces the Fracture Incidence in a Growing Mouse Model of Osteogenesis Imperfecta.
Shi C; Hu B; Guo L; Cao P; Tian Y; Ma J; Chen Y; Wu H; Hu J; Deng L; Zhang Y; Yuan W
J Bone Miner Res; 2016 May; 31(5):1003-14. PubMed ID: 26679066
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study.
Otaify GA; Aglan MS; Ibrahim MM; Elnashar M; El Banna RA; Temtamy SA
Osteoporos Int; 2016 Jan; 27(1):81-92. PubMed ID: 26138583
[TBL] [Abstract][Full Text] [Related]
15. Low Dose of Bisphosphonate Enhances Sclerostin Antibody-Induced Trabecular Bone Mass Gains in Brtl/+ Osteogenesis Imperfecta Mouse Model.
Olvera D; Stolzenfeld R; Marini JC; Caird MS; Kozloff KM
J Bone Miner Res; 2018 Jul; 33(7):1272-1282. PubMed ID: 29544018
[TBL] [Abstract][Full Text] [Related]
16. Effect of rapamycin on bone mass and strength in the α2(I)-G610C mouse model of osteogenesis imperfecta.
Bateman JF; Sampurno L; Maurizi A; Lamandé SR; Sims NA; Cheng TL; Schindeler A; Little DG
J Cell Mol Med; 2019 Mar; 23(3):1735-1745. PubMed ID: 30597759
[TBL] [Abstract][Full Text] [Related]
17. Combinatorial Inhibition of Myostatin and Activin A Improves Femoral Bone Properties in the G610C Mouse Model of Osteogenesis Imperfecta.
Omosule CL; Joseph D; Weiler B; Gremminger VL; Silvey S; Jeong Y; Rafique A; Krueger P; Kleiner S; Phillips CL
J Bone Miner Res; 2022 May; 37(5):938-953. PubMed ID: 35195284
[TBL] [Abstract][Full Text] [Related]
18. Are Changes in Composition in Response to Treatment of a Mouse Model of Osteogenesis Imperfecta Sex-dependent?
Boskey AL; Marino J; Spevak L; Pleshko N; Doty S; Carter EM; Raggio CL
Clin Orthop Relat Res; 2015 Aug; 473(8):2587-98. PubMed ID: 25903941
[TBL] [Abstract][Full Text] [Related]
19. Acute and long-term effects of zoledronate in adult patients with osteogenesis imperfecta. An observational Spanish study with five years of follow-up.
Pavón de Paz I; Rosado Sierra JA; Pérez Blanco C; Modroño Móstoles N; Guijarro de Armas G; Navea Aguilera C
Endocrinol Diabetes Nutr (Engl Ed); 2019 Feb; 66(2):108-116. PubMed ID: 30077631
[TBL] [Abstract][Full Text] [Related]
20. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC
J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]